Navigation Links
Generic Drugs: World Market Outlook 2011-2021
Date:11/2/2011

ric Drugs (Generics)

2.1.1 Authorised, Branded and True Generics

2.2 The 'Evergreening' of Pharmaceuticals

2.3 Restraints Facing the World Pharmaceutical Market

2.4 Branded Pharmaceuticals: End of a Business Model?

2.5 US Regulations

2.5.1 Obtaining FDA Approval: NDAs and ANDAs

2.5.2 The Hatch-Waxman Act Title 1: Promotion of Generic Drugs

2.5.3 The Hatch-Waxman Act Title 2: Incentives for the Branded Industry

2.5.4 Consequences of the Hatch-Waxman Act

2.5.5 Me First: Timing as a Crucial Factor

2.6 European Regulations

2.6.1 Generics' Entry into the European Markets

2.6.2 Further Protection of Branded Products in the European Market

2.6.3 Variations among European Countries

2.6.4 Moving Towards Standardisation

2.6.5 The 8+2+1 Rule

2.7 Japanese Regulations

2.8 Compulsory Licensing

2.9 Generic Drugs: Overview

3. The World Generic Drugs Market, 2011-2021

3.1 The World Generic Pharmaceuticals Market in 2010 

3.2 Generic Products to Benefit from Patent Expiries

3.2.1 Sales Forecast for the World Generic Drugs Market, 2011-2015

3.2.2 Sales Forecast for the World Generic Drugs Market, 2016-2021

3.3 Global Market Breakdown, 2011-2021

4. Leading Companies in the World Generics Market

4.1 Teva Pharmaceutical Industries - Prospects from 2011

4.1.1 ANDAs and Approvals

4.1.2 M&A Activity

4.2 Sandoz - Prospects from 2011

4.3 Mylan - Prospects from 2011

4.3.1 Mylan's Acquisition of Bioniche Pharma Holdings

4.4 Apotex - Prospects from 2011

4.5 Hospira - Prospects from 2011

4.5.1 Acquisition of Orchid's Generic Injectable Pharmaceutical Business

4.5.2 Hospira's Acquisition of Javelin Pharma

4.6 Watson - Prospects from 2011

4.6.1 ANDAs and Approvals

4.6.2 M&A Activity

4.6.3 Eden Becomes
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Multi-therapy Drugs: Opportunities for Generics & Biosimilars
2. Perrigo Announces Launch of Generic Version of Elestat®
3. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
4. Mylan Receives Approval for Generic Version of MS Contin® Tablets
5. FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers Access to Lower-Cost Generic Drugs
6. INNOPHARMA Receives FDA Approval of Generic Olanzapine Injection
7. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
8. Par Pharmaceutical Begins Shipment of Generic Zyprexa® Zydis®
9. FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder
10. Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape
11. Prasco® Selected as Eli Lilly and Companys Authorized Generics Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... IRVINE, Calif., Aug. 4, 2015  Syneron Medical Ltd. (NASDAQ: ... announced financial results for the three month period ended June ... Recent Non-GAAP 1 Highlights: , ... constant currency. , North American product sales grew 45% ... in constant currency, including 14% product growth in the EMEA ...
(Date:8/3/2015)...   The Intellectual Property and Science business ... of intelligent information for businesses and professionals announced ... R&D Factbook , the biopharmaceutical industry,s leading resource ... in R&D, the analysis identifies a surge in ... forecasts sales to reach $1.3 trillion by 2018. ...
(Date:8/3/2015)... GLENWOOD, Ill. , Aug. 3, 2015  Landauer, ... personal and environmental radiation measurement and monitoring, outsourced medical ... announced it will release financial results for the fiscal ... August 10, 2015. The Company will ... August 11, 2015 at 9:00 a.m. Central Time (10:00 ...
Breaking Medicine Technology:Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17Pharma Sales to Grow Beyond $1 Trillion 2Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2
... Feb. 1, 2011 Anthera Pharmaceuticals, Inc. (Nasdaq: ... treat serious diseases associated with abnormal auto-immune responses and ... Thompson to its Board of Directors. Currently, Dr. Thompson ... founder and Managing Director of Strategicon Partners, an investment ...
...  China Medicine Corporation (OTC Bulletin Board: ... and distributor of Western pharmaceuticals, traditional Chinese medicines ... Republic of China, today announced that the Company ... Ministry of Agriculture ("MOA") for the Company,s proprietary ...
Cached Medicine Technology:Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors 2China Medicine Corporation Receives Manufacturing License for rADTZ 2China Medicine Corporation Receives Manufacturing License for rADTZ 3
(Date:8/4/2015)... ... August 04, 2015 , ... Wimbledon Health Partners , ... NCV testing, announced their collegiate division, Wimbledon U , continues to not ... program at a time. , “Wimbledon U welcomes the eight new ...
(Date:8/4/2015)... ... ... An article published July 27th by the Providence Journal detailed ... people to lose weight. Specifically the study compared control patients with those who were ... financial incentive to the overall incentive of increased health. According to Michael Feiz, M.D., ...
(Date:8/4/2015)... , ... August 04, 2015 , ... Bayco Products, Inc. ... enough to fit, for example, on hard hats that have a flip-up face shield. ... allows users to work without having to remove their headlamp when raising or ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA ... only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in ...
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide Power Products acquires new ... its reach in Texas. Effective July 1st of this year, Worldwide Power Products ... With the North Texas acquisition, Worldwide Power Products (“WPP”) now services 1000 ...
Breaking Medicine News(10 mins):Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:North Texas Acquisition Press Release 2
... named REACH: Registration, Evaluation and Authorization of Chemicals, has shifted ... manufacturers. ,The chemical companies would be bound by ... of their business. ,This law aims to make ... safe for users and the environs. ,The European ...
... Surgical Adjuvant Breast and Bowel Project (NSABP) B-33 ... Cancer Symposium, showed that// postmenopausal women with hormone ... years of tamoxifen were 56% less likely to ... who received placebo (P=0.004). ,“Aromasin provided ...
... in occupational settings and in the environment has been ... Journal of Occupational and Environmental Medicine, official publication of ... is a special issue providing updates on particles and ... types of studies for some particles in terms of ...
... soy-based substance. A US based study finds: BBIC improves ... multiple// sclerosis. ,A group of animals with ... animals also suffering from the same disease received a ... to walk, while those that didn't get the drug ...
... the Bombay Hospital and three other firms are planning to ... ,The Jaipur Development Authority would allot land for the five ... a Rs.2 billion Medi-City to be built here in three ... ,The state plans to be strict with the investors ...
... In the absence of vaccine against HIV/AIDS, the 'social vaccine' ... of the deadly virus, a top UN official here said ... to fight against the HIV/AIDS," said Peter Piot, executive director ... vaccine I mean to create a mass awareness to educate ...
Cached Medicine News:Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 2Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 3Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 4Health News:Inhaled Particles Increases the Risk of Lung Cancer 2
... detects the presence of Hemoglobin S ... of reconstituted solubility buffer and 20l of ... cell hemoglobin control. Each test kit contains ... two buffer dispensing caps and two vials ...
... Streck Cytometry Concentrate is for use ... by flow cytometry. Each 70ml bottle of ... fluid with distilled water. Compared to Cubitainers, ... usable space and saves money without compromising ...
... is an assayed control for monitoring immunophenotyping ... accuracy and reproducibility of all the steps ... red blood cell lysis. Reference values for ... B lymphocytes, granulocytes, monocytes, and NK cells. ...
Use Streck-Sheath to count and classify white blood cells on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf life is two years from date of manufacture...
Medicine Products: